Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 12 of 12 for “"AONS"”.

  1. PLP-Dependent α-Oxoamine Synthases: Phylogenetic Analysis, Structural Plasticity, and Structure-Function Studies on 5-Aminolevulinate Synthase

    … (ALAS) and 8-amino-7-oxononanoate synthase (AONS) are two of four homodimeric members of the alpha-oxoamine synthase family of pyridoxal 5'-phosphate (PLP)-dependent enzymes. The evolutionary relationships among α-oxoamine synthases representing a broad taxonomic and phylogenetic spectrum …

    usf Repository record for PLP-Dependent α-Oxoamine Synthases: Phylogenetic Analysis, Structural Plasticity, and Structure-Function Studies on 5-Aminolevulinate Synthase (opens in a new tab)

  2. ENGINEERING T LYMPHOCYTES WITH KNOWN SPECIFICITY AND MODIFIED FUNCTION FOR PERSONALIZED IMMUNE THERAPY

    … splicing-modifying Antisense Oligonucleotides (AONs) concurrently with mRNA coding for HBV-specific TCRs. Using AONs targeting perforin or interferon-γ we first demonstrated that it is possible to modify both specificity and function of lymphocytes. We then designed AONs inducing the skipping of …

    nus Repository record for ENGINEERING T LYMPHOCYTES WITH KNOWN SPECIFICITY AND MODIFIED FUNCTION FOR PERSONALIZED IMMUNE THERAPY (opens in a new tab) Download file for ENGINEERING T LYMPHOCYTES WITH KNOWN SPECIFICITY AND MODIFIED FUNCTION FOR PERSONALIZED IMMUNE THERAPY (opens in a new tab)

  3. Molecular and preclinical aspects of antisense oligonucleotide treatment for myotonic dystrophy type 1

    … available for DM1. Antisense oligonucleotides (AONs) complementary to the (CUG)n repeat constitute a promising tool for treatment of DM1. We performed a broad screening of chemically modified (CAG)n AONs for their ability to reduce expanded DMPK mRNA levels. We found that AON chemistry is an …

    radboud Repository record for Molecular and preclinical aspects of antisense oligonucleotide treatment for myotonic dystrophy type 1 (opens in a new tab) Download PDF for Molecular and preclinical aspects of antisense oligonucleotide treatment for myotonic dystrophy type 1 (opens in a new tab)

  4. Verfahren zur effizienten nanopartikel-vermittelten Einschleusung therapeutischer Nukleinsäuren in Zellen des Immunsystems zur Gentherapie immunologischer Erkrankungen

    … erfolgte durch antisense Oligonukleotide (AONs) und durch small interfering RNAs (siRNA). Zur effizienten und sicheren Einschleusung (Transfektion) der Oligonukleotide in die Zielzellen wurden Nanopartikel verwendet. Die Wirkung wurde zunächst in vitro an murinen und humanen Zellen und …

    qucosa-diss

  5. Studies on human ribonuclease H1 and its action on 2'-fluoroarabinose oligonucleotide hybrid substrates

    … of the therapeutic efficacy of next-generation AONs with novel structures requires an in vitro system involving, purified, highly active RNase H1 of human cells, and a full understanding of the catalytic mechanism of the enzyme. The goal of project 1 described in chapter 3, was to determine the …

    temple Repository record for Studies on human ribonuclease H1 and its action on 2'-fluoroarabinose oligonucleotide hybrid substrates (opens in a new tab)

  6. Attack monitoring and localization in an all-optical network

    … (E-O) conversion within the network. Although AONs are a viable technology for future telecommunication and data networks, little attentions has been devoted to the intrinsic differences between AONs and existing existing electro-optic/electronic networks in issues of security management. …

    iastate Repository record for Attack monitoring and localization in an all-optical network (opens in a new tab)

  7. Bioconjugate Strategies for Antisense Therapeutic Delivery to Glioblastoma Stem Cells

    … including antisense oligonucleotides (AONs) and small interfering ribonucleic acids (siRNAs), are powerful tools for regulating genes, making them a promising therapy for diseases such as cancer where oncogenic genes are over-expressed. The delivery of antisense therapeutics to target …

    toronto-retro Repository record for Bioconjugate Strategies for Antisense Therapeutic Delivery to Glioblastoma Stem Cells (opens in a new tab)

  8. Exon skipping as a therapeutic strategy in dysferlinopathy

    … they could be removed simultaneously. Thirteen AONs masking exon 37, 38 and intron 37-38 of human dysferlin pre-mRNA were designed. The AON-based splice switching strategy was screened in vitro. Out of thirteen AONs only five demonstrated low level of skipping exon 38. The activity of these …

    fu-berlin Repository record for Exon skipping as a therapeutic strategy in dysferlinopathy (opens in a new tab)

  9. Study on Human 5-Aminolaevulinate Synthase and the Molecular basis for Pyridoxine Responsive X-Linked Sideroblastic Anaemia

    … ALAS2 and 2-amino-3-oxononanoate synthase (AONS), a closely related PLP-dependent enzyme, permitted the constriction of a model structure for human ALAS2, using the sequence alignment of AONS as a template. The location of human mutations in the model structure of ALAS2 provides a rational …

    soton Download PDF for Study on Human 5-Aminolaevulinate Synthase and the Molecular basis for Pyridoxine Responsive X-Linked Sideroblastic Anaemia (opens in a new tab)

  10. UNBIASED FUNCTIONAL VALIDATION OF ALTERNATIVE-SPLICED ISOFORMS IN CANCER

    … (PCa). Upon targeting selected events using AONs, we noticed a preferential depletion of the malignant cells rather than healthy ones. Thus, this thesis offers not only a novel computational method to improve diagnostic power, but also a potential targeted therapy for cancer.

    nus Repository record for UNBIASED FUNCTIONAL VALIDATION OF ALTERNATIVE-SPLICED ISOFORMS IN CANCER (opens in a new tab) Download file for UNBIASED FUNCTIONAL VALIDATION OF ALTERNATIVE-SPLICED ISOFORMS IN CANCER (opens in a new tab)

  11. RNA-based therapies for dysferlinopathies

    … in a patient that was ambulant until high age. AONs of the tricyclo-DNA backbone chemistry were applied, which due to the additional two carbon ring entities within the single nucleoside are more rigid and show higher binding affinity to RNA than DNA does. The in vitro and in vivo application of …

    fu-berlin Repository record for RNA-based therapies for dysferlinopathies (opens in a new tab)

  12. Antisense-mediated splicing correction approaches for retinal dystrophies and dysfunctions

    … part of two classes: antisense oligonucleotides (AONs) and chimeric or adapted small nuclear RNAs (snRNAs). They function by altering how the splicing machinery recognize a target sequence, usually an exon, allowing to increase its presence (exon inclusion) or decrease it (exon skipping) in mature …

    trento Repository record for Antisense-mediated splicing correction approaches for retinal dystrophies and dysfunctions (opens in a new tab)